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Background: The role of serum uric acid as an independent predictor of cardiovascular disease and death is
uncertain in the general population. Adjustments for additional cardiovascular risk factors have not been consistent.
We examined the association of serum uric acid with all-cause mortality, ischemic stroke and myocardial infarction
in a prospective population based study, with several traditional and non-traditional risk factors for cardiovascular
disease included in the model.
Methods: A population-based prospective cohort study was performed among 2696 men and 3004 women.
Endpoints were all-cause mortality after 15 years, and fatal or non-fatal myocardial infarction (MI) and ischemic
stroke after 12 years.
Results: 1433 deaths, 659 MIs and 430 ischemic strokes occurred during follow-up. Fully adjusted Cox regression
analyses showed that per 1 SD (87 μmol/L) increase in serum uric acid level, the risk of all-cause mortality increased
in both genders (hazard ratios, HR men; 1.11, 95% CI 1.02-1.20, women; 1.16, 1.05-1.29). HRs and 95% CI for stroke
were 1.31, 1.14-1.50 in men, 1.13, 0.94-1.36 in women, and 1.22 (1.09, 1.35) in the overall population. No independent
associations were observed with MI.
Conclusion: Serum uric acid was associated with all-cause mortality in men and women, even after adjustment for
blood pressure, estimated GFR, urinary albumin/creatinine ratio, drug intake and traditional cardiovascular risk factors.
After the same adjustments, serum uric acid was associated with 31% increased risk of stroke in men.
Keywords: All-cause mortality, Gender, Myocardial infarction, Stroke, Uric acidBackground
Uric acid is the breakdown product of purines from DNA,
RNA, ATP and cAMP. In this process hypoxanthine is con-
verted by the enzyme xanthine oxidase to xanthine and fur-
ther to uric acid. Both steps induce the release of free
radicals. Uric acid may accumulate in the body due to in-
creased production (cell death, intake of alcohol or purine
rich diet) or decreased elimination (impaired renal function,
use of diuretics). Epidemiologic studies show that mean
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reproduction in any medium, provided the orto the 1970s, from less than 210 μmol/L to 360-390 μmol
[1]. Pre-menopausal women tend to have lower levels than
men, probably because of the uricosuric effect of estrogens
[2]. The relationship between serum uric acid and cardio-
vascular disease is not clear. Some epidemiologic studies
have reported a relationship between serum uric acid and
several cardiovascular conditions [3-10], whereas others
have not observed such links [11-15]. The National Health
and Nutrition Examination Survey (NHANES I study) [3]
reported a significant risk for cardiovascular death with in-
creasing serum uric acid levels. The Framingham Heart
study, on the other hand, was not able to confirm these
findings when use of diuretics was adjusted for [11]. Two
large cohort studies from Japan and Korea, each with 9-10
years follow up could not confirm that serum uric acid wasal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[12,13]. It has been argued that previous studies may not
have sufficiently accounted for differences in gender or for
risk factors being strongly related to serum uric acid levels,
e.g., use of diuretics or renal factors, such as glomerular fil-
tration rate (GFR) and renal dysfunction measured as urin-
ary albumin excretion.
The purpose of the present study was to address uric
acid as putative cardiovascular risk factor in a Caucasian
population followed for more than 12 years. In order to
do so, we chose a stepwise approach with models in-
cluding various covariates that have and have not been
included in previous studies.
Methods
Study population
The Tromsø Study is a series of population-based, pro-
spective surveys of inhabitants of the municipality of
Tromsø, Norway [16]. In 1994/95, 27.158 subjects were
screened (77% of eligible subjects). All participants at
the age of 55-75 years and 5-10% of the other age
groups ≥ 25 years were invited to a second visit including
a more comprehensive examination 4-6 weeks later. Of
the 9057 individuals who were invited 6862 participated
(attendance rate 75%). Persons with known previous MI
(n = 402), ischemic stroke (n = 190) or diabetes (n = 308),
defined as self-reported diabetes, use of antidiabetic medi-
cation, HbA1c > 6.5% or non-fasting plasma glucose ≥10.0
mmol/L, were excluded. Data on uric acid was available
in 5700 subjects (Figure 1). The Tromsø Study was
conducted by the University of Tromsø in cooperation
with The National Health Screening Service. The Regional
Committee for Medical Research Ethics approved the
study, and all participants gave their written consent.
Measurements
All measurements and information on risk factors were
obtained from baseline data of the 4th Tromsø Study in
1994 /95. Information about presence of diabetes, smoking
habits and physical activity was obtained from a self-
administered questionnaire. Blood pressure was recorded
in triplet (Dinamap) after 5-min seating, the mean of the
second and third measurement was used. Hypertension
was defined as systolic blood pressure (SBP) ≥ 140 mmHg
and/or diastolic pressure (DBP) ≥ 90 mmHg and/or current
use of antihypertensive medication. Physical activity was
classified as active (> 1 hour physical activity/week) or in-
active (all others). Smoking habits were classified as non-
smokers or current smokers. Serum HDL-cholesterol was
measured after precipitation of lower-density lipoprotein
with heparin and manganese chloride. Serum uric acid
was measured by photometry with COBAS® instruments
(Roche diagnostics, Switzerland) using an enzymatic col-
orimetric test, the uricase/ PAP method. Reference valueswere 140-340 μmol/L (2.4-5.7 mg/100 mL) for females
and 200-415 μmol/L (3.4-7.0 mg/100 mL) for males. Cre-
atinine was analyzed by a modified Jaffe reaction, but since
creatinine-based estimation of GFR is better validated
for enzymatic creatinine measurements, 111 plasma
samples from the 1994/95 survey were thawed and rea-
nalysed with an enzymatic method (Modular P/Roche).
Values were fitted to a linear regression model, and
recalibrated creatinine values were calculated for all
participants. Estimated GFR was calculated according
to the CKD-EPI formula [17]: eGFR= 141 × min(SCr/k,1)
a ×
max(SCr/k,1)
-1.209 × 0.993age × ([1.018 if female] and ×
[1.159 if black]) where SCr is serum creatinine (mg/dL),
k is 0.7 for females and -0.411 for males, min indicates
the minimum of SCr/k and max indicates the maxiumum
of SCr/k). Albuminuria was reported as albumin/creatinine
ratio (ACR, mg/mmol, urinary albumin and creatinine
analyses; kits from ABX Diagnostics, Montpellier, France).
For each subject, ACR was measured in fresh samples of
each of 3 separate urine specimens and the mean of all 3
was used in the analyses.
Outcomes
The endpoints were death from any cause, first ever non-
fatal or fatal myocardial infarction or ischemic stroke. Ad-
judication of hospitalized and out-of-hospital events was
performed by an independent endpoint committee, who
thoroughly reviewed data from hospital and out-of-hospital
journals, autopsy records and death certificates. Event
ascertainment followed a detailed protocol according to
established diagnostic criteria. Each case was reviewed
separately. Stroke was defined according to the WHO
definition, only ischemic strokes were included [18].
Individuals who had died, moved, or emigrated from
Tromsø were identified through the population Registry
of Statistics Norway. The national 11-digit identification
number allowed a linkage to the population Registry of
Statistics Norway and ensured a complete follow-up status
for all-cause mortality until November 30th, 2010 (follow-
up time 15 years). The cardiovascular (CV) endpoint regis-
try was completed until December 31, 2007 (follow-up
time 12 years). Data were censored for date of registered
emigration, or deaths from causes other than myocardial
infarction and stroke.
Statistics
Data are given as mean ± SD or median and interquar-
tile range. Uric acid was categorized into gender-specific
tertiles. Crude and age-adjusted incidence rates were cal-
culated as events per 1000 person years at risk. Age-
adjustment of incidence rates was performed on 10 year
age groups with the population of Tromsø in 1995 as the
standard population. Multiple linear regression analyses
were performed with uric acid as the dependent variable.
      The Tromsø Study 1994/-95, Phase 2: 
All participants aged 55-75 years and 5-10 % 
of all other age groups  25 years invited 
9057 invited, 6862 consented and attended  
                    (75% of the invited) 
      The Tromsø Study 1994/-95, Phase 1: 
      All inhabitants of the municipality of      
          Tromsø > 25 years were invited 
                27.158 subjects attended  
                  (77 % of the invited) 
  5700 individuals; 2696 men, 3004 women 
  Number of endpoints: 
  659 myocardial infarctions, 430 ischemic   
  strokes, and 1433 deaths from all causes 
506 individuals excluded  
due to previous myocardial 
infarction (402) or stroke (190) 
or both (86) 
308 individuals excluded 
due to the presence of diabetes* 
348 individuals had missing 
values for serum uric acid 
Figure 1 Selection of the study population. * Self-reported diabetes mellitus and/or use of antidiabetic medication and/or HbA1c > 6.5%
and/or non-fasting glucose ≥ 10.0 mmol/L.
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(BMI), high density lipoprotein cholesterol (HDL), total
cholesterol, smoking status and physical activity. Renal co-
variates (estimated GFR and ACR) and use of diuretics or
antihypertensive drugs were also added to the models in
the multivariable analyses. ACR was logarithmically trans-
formed. Cox proportional hazard models were used to in-
vestigate associations of uric acid with cardiovascular
outcomes and mortality, calculated per 1 SD (87 μmol/L)
change in uric acid, in unadjusted, age-adjusted and multi-
variable analyses. The proportional hazard assumption was
checked by visual inspection of the -log-log survival
curves. Tests for interactions and non-linearity (by quad-
ratic terms) were assessed in separate models. Non-lineareffects were also explored in fractional polynomial regres-
sion models. P values < 0.05 were considered statistically
significant. Most analyses were run using SPSS software
version 15.0 (SPSS, INC, Chicago, Illinois), fractional poly-
nomial regression models were performed with STATA/
MP 12.1 (Stata Corp LP, College Station, Texas).
Results
Baseline characteristics
Mean serum uric acid was 357 ± 84 μmol/L for men and
276 ± 70 μmol/L for women. Figure 2 shows serum uric
acid concentrations according to gender and age. In both
genders, increasing uric acid was associated with a poorer
risk profile in terms of elevated BMI, blood pressure,
Age Groups, Years
Serum Uric Acid, Women
Serum Uric Acid, Men
Serum
Uric Acid,
µmol/l
150
250
350
450
550
25 - 29 30 - 39 40 - 49 50 - 59 60 - 69 70
Figure 2 Serum uric acid levels by gender and age groups. Mean (SD).
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tivity, renal function and HDL were lower with increasing
uric acid concentrations. Only a few subjects were using
diuretics and anti-hypertensive medication at baseline in
1994/95 (Table 1).
The association of serum uric acid with renal function and
CV risk factors
The correlation between uric acid and age differed in men
and women (men; r = -0.09, p < 0.001, women; r = 0.17, p <
0.001, Pearson’s correlation coefficients), and tested signifi-
cant for gender interaction (P < 0.001). Results of the mul-
tiple linear regression analyses are given in Table 2. In both
genders, standardized beta-coefficients were highest for
BMI, HDL-cholesterol, total cholesterol, and GFR. The
addition of renal factors (eGFR and ACR; model 5) into
the model including drug intake and traditional cardiovas-
cular risk factors, contributed significantly to variation of
serum uric acid; adjusted R2 increased from 0.19 to 0.23 in
men, from 0.20 to 0.27 in women, and from 0.20 to 0.40
in pooled analyses for men and women together. ACR was
independently associated with serum uric acid in women,
but not in men, and there was a significant interaction with
gender (P = 0.005).
Event rates
Number of events during follow-up were 659 first ever
cases of fatal or non-fatal MI, 430 fatal or non-fatal is-
chemic strokes, and 1433 deaths from all causes. Median
observation time was 12.5 years for myocardial infarction
and ischemic stroke, and 15.7 years for all-cause mortality.
Crude and age-adjusted incidence, for MI and ischemic
stroke, picturing absolute risk rates according to increasingtertiles of serum uric acid, are shown in Figure 3. Age-
adjusted incidence rate for myocardial infarction was sig-
nificantly higher in the upper serum uric acid tertile
among men, but not in women. Increasing crude and age-
adjusted incidence rates with higher levels of uric acid
were observed in both genders for ischemic stroke.
Associations between serum uric acid and outcome
variables (Cox proportional hazard models)
In both genders, P-values for linear, increasing trend
were <0.001 for all endpoints in multivariable, Cox pro-
portional hazard models where the lowest serum uric
acid tertile was reference (data not shown). In multivari-
able analyses calculated per 1 SD (87 μmol/L) increase
in uric acid (Table 3), uric acid was independently asso-
ciated with all-cause mortality in men (HR, 95% CI;
1.11, 95% CI 1.02-1.20), women (HR, 95% CI; 1.16, 1.05-
1.29), and in the total population (men and women; HR,
95% CI: 1.13, 1.06-1.21). In fully adjusted, multivariable
models, serum uric acid was not independently associated
with MI in any gender or in the mixed population. In both
genders, uric acid lost significance when lipids were intro-
duced as covariates. Serum uric acid was strongly associ-
ated with ischemic stroke in men after multivariable
adjustments (HR, 95% CI: 1.31, 1.14-1.50). In contrast, sig-
nificance was lost among women after adjustments for
blood pressure and BMI. Test for gender interaction was
not significant (P = 0.19). In multivariable analysis of the
mixed population, adjusted for sex, 87 μmol/L increase in
uric acid was associated with a 24% increase in risk of fu-
ture ischemic stroke (Table 3). Tests for non-linearity in
fractional polynomial models for associations of serum
uric acid with the three endpoints were not significant in
Table 1 Baseline characteristics according to gender and serum uric acid tertiles
Men
SUA tertiles I ≤ 317μmol/L II 318-380 μmol/L III 381-976 μmol/L P value for linear trend
N 896 902 898
Age, years 60 ± 10 59 ± 10 59 ± 11 <0.001
Serum uric acid (SUA), μmol/L 276 ±33 348 ± 18 449 ± 70 -
BMI, kg/m2 24.7 ± 2.9 25.8 ± 3.0 27.3 ± 3.4 <0.001
SBP, mm Hg 144 ± 20 144 ± 20 146 ± 20 <0.001
DBP, mm Hg 84 ± 12 85 ± 12 86 ± 12 <0.001
Hypertension, n (%) 482 (54%) 546 (61%) 571 (64%) <0.001
Total cholesterol, mmol/l 6.35 ± 1.19 6.40 ± 1.20 6.73 ± 1.20 <0.001
HDL cholesterol, mmol/l 1.51 ± 0.40 1.40 ± 0.39 1.26 ± 0.38 <0.001
GFR ckd-epi, ml/min/1.73m2 96.7 (90.9, 102.4) 95.5 (88.0, 102.5) 93.4 (84.0, 101.5) <0.001
ACR mg/mmol 0.55 (0.38, 0.96) 0.51 (0.33, 1.01) 0.54 (0.34, 1.13) 0.021
Use of antihypertensive drugs, n (%) 74 (8%) 87 (10%) 155 (17%) <0.001
Use of diuretics , n (%) 2 (0.2%) 5 (0.6%) 13 (1.4%) <0.001
Current smoker, n (%) 351 (39%) 300 (33%) 294 (33%) <0.001
Physically active, n (%) 301 (33%) 268 (30%) 244 (27%) <0.001
Women
SUA tertiles I ≤ 244 μmol/L II 245-297 μmol/L III 298-681 μmol/L P value for linear trend
N 1002 1001 1001
Age, years 58 ± 11 60 ± 10 62 ± 9 <0.001
Serum uric acid (SUA), μmol/L 206 ± 28 269 ± 15 354 ± 54 -
BMI, kg/m2 24.0 ± 3.5 25.6 ± 3.8 27.7 ± 4,6 <0.001
SBP, mm Hg 138 ± 23 143 ± 23 151 ± 25 <0.001
DBP, mm Hg 78 ± 13 81 ± 12 85 ± 14 <0.001
Hypertension, n (%) 446 (45%) 534 (53%) 679 (68%) <0.001
Total cholesterol, mmol/l 6.63 ± 1.39 6.82 ± 1.29 7.14 ± 1.32 <0.001
HDL cholesterol, mmol/l 1.76 ± 0.43 1.69 ± 0.43 1.54 ± 0.42 <0.001
GFR ckd-epi, ml/min/1.73m2 96.9 (90.5,103.0) 93.6 (86.0, 99.4) 89.7 (79.4, 97.1) <0.001
ACR, mg/mmol 0.62 (0.41, 0.96) 0.58 (0.41, 0.93) 0.64 (0.42, 1.14) <0.001
Use of diuretics, n (%) 3 (0.3%) 7 (0.7%) 39 (3.9%) <0.001
Use of antihypertensive drugs, n (%) 65 (6.5%) 107 (11%) 148 (15%) <0.001
Current smoker, n (%) 339 (34%) 315 (32%) 278 (28%) 0.001
Physically active, n (%) 162 (16%) 177 (18%) 118 (12%) <0.002
The Tromsø Study 1994/95.
BMI: Body mass index. SBP: Systolic blood pressure. DBP: Diastolic blood pressure Hypertension: SBP ≥140 mmHg and/or DBP ≥90 mmHg and/or self-reported use
of antihypertensive medication. Physical active: Self-reported hard physical activity ≥1 hr per week (yes / no).
GFR: Glomerular Filtration Rate according to the CKD EPI formula [17]. ACR: Urinary albumin/creatinine ratio (mean of 3 urine samples).
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without exclusion of persons with diabetes and previous
cardiovascular disease. Risk estimates for uric acid and
myocardial infarction in fully adjusted analyses did not
change substantially (HR and 95% CI for men were 1.06,
0.99-1.14, p = 0.06 and for women 1.04, 0.92-1.14, p = 0.5).
We also stratified the study population according to serum
uric acid levels higher or lower than the hospital labora-
tory’s upper reference range. Belonging to the group withhigher uric acid levels was not significantly associated with
myocardial infarction in men (P = 0.26) or women (P =
0.27) after multivariable adjustments.
Discussion
In this 12-15 year prospective study of 5700 men and
women from the general population where persons with
known diabetes or cardiovascular disease were excluded,
a 1 SD (87 μmol/L) increase in serum uric acid was
Table 2 Multiple regression analysis with cardiovascular and renal covariants, and serum uric acid as dependent variable
Men n = 2696 Women n = 3004 Men and women n = 5700
β (95% CI*) Std. β-coeffcent.ϯ P-value β (95% CI*) Std. β-coeffcent.ϯ P-value β (95% CI*) Std. β-coeffcent.ϯ P-value
Model 1
Intercept 175 (143, 208) - <0.001 71 (52, 90) - <0.001 128 (108, 148) - <0.001
Age −0.70 (-0.10, -0.39) −0.09 <0.001 0.55 (0.30, 0.80) 0.08 <0.001 −0.39 (-0.61, -0.17) −0.05 0.001
BMI 8.29 (7.38, 9.21) 0.33 <0.001 5.31 (4.73, 5.88) 0.32 <0.001 6.79 (6.21, 7.37) 0.30 <0.001
SBP 0.06 (-0.10, 0.21) 0.01 0.49 0.24 (0.13, 0.35) 0.08 < 0.001 0.24 (0.13, 0.35) 0.06 <0.001
Adjusted R2 0.12 0.15 0.10
Model 2
HDL-cholesterol −44.42 (-52.09, -36.76) −0.22 <0.001 -27.68 (-33.12,-22.23) −0.17 <0.001 −61.58 (-66.42, -56.74) −0.32 <0.001
Cholesterol 10.12 (7.70, 12.54) 0.15 <0.001 6.38 (4.50, 8.26) 0.12 <0.001 6.33 (4.67, 7.99) 0.10 <0.001
Adjusted R2 0.17 0.18 0.19
Model 3
Antihypertensive
Drugs 26.10 (16.76, 35.44) 0.10 <0.001 14.19 (6.55, 21.83) 0.06 0.001 20.37 (13.66, 27.08) 0.07 <0.001
Diuretics 66.90 (33.13, 99.98) 0.07 <0.001 69.14 (51.01, 87.28) 0.13 <0.001 54.52 (35.75, 73.29) 0.07 <0.001
Adjusted R2 0.18 0.20 0.20
Model 4
Current smoker −7.73 (-13.81, -1.63) −0.04 0.01 2.07 (-3.02, 7.16) 0.01 0.4 −0.80 (-5.23, 3.62) −0.004 0.7
Physical activity −7.29 (-13.56, -1.02) −0.04 0.02 1.17 (-5.27, 7.61) 0.01 0.7 11.28 (6.35, 16.20) 0.05 <0.001
Adjusted R2 0.19 0.20 0.20
Model 5
GFR ckd-epi −1.76 (-2.05, -1.48) −0.28 <0.001 −1.73 (-1.94, -1.51) −0.32 <0.001 −1.74 (-1.91,-1.56) −0.27 <0.001
logACR 4.09 (-2.58, 10.76) 0.02 0.23 15.41 (9.28, 21.55) 0.08 < 0.001 8.09 (3.58, 12.61) 0.04 <0.001
Gender - - - - - - - - 76.87 (73.08, 80.66) 0.44 <0.001
Adjusted R2 0.23 0.27 0.40
*Confidence interval. ϯStandarized β-coeffcient. Gender: 1 = male, 0 = female, GFR: Glomerular filtration rate according to the CKD EPI formula [17].
ACR: urinary albumin/creatinine ratio (mean of 3 urine samples) logACR: logarithmic transformation of ACR. Model 1: Age, body mass index.
(BMI), systolic blood pressure (SBP). Model 2: Model 1 + HDL-cholesterol and total cholesterol. Model 3: Model 2 + use of diuretics and other anti-hypertensive medication. Model 4: Model 3 + current smoking and
physical activity (self-reported hard physical activity ≥1 hr per week; yes = 1 / no = 0), current smoking (yes = 1 / no = 0). Model 5: Model 4 + renal factors added (GFR the CKD-EPI and logACR).
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Serum Uric Acid
First ever fatal or non-fatal
ischemic stroke
Serum Uric Acid
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Age-adjusted incident rates 
Crude incident rates
Incidence Rates (per 1000 person-years at risk)
MEN MEN MEN WOMEN WOMEN WOMEN
Tertile I Tertile II Tertile III Tertile I Tertile II Tertile III
 317 318-380 381  244 245-297 298
µmol/L µmol/L µmol/L µmol/L µmol/L µmol/L
MEN MEN  MEN   WOMEN WOMEN WOMEN
Tertile I Tertile II Tertile III Tertile I Tertile II Tertile III
 317 318-380 381  244 245-297 298
µmol/L µmol/L µmol/L µmol/L µmol/L µmol/L
Figure 3 Crude and age-adjusted incidence rates by serum uric acid tertiles. † : P < 0.05. ‡ : P < 0.001 (differences between tertiles were
tested for using a normal test with continuity correction, tertile 1 was reference).
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mic stroke in men, and all-cause mortality risk was in-
creased in both genders, with 11% in men, and 16% in
women, after multivariable adjustments. Gender-adjusted,
multivariable analyses of pooled data from both men and
women showed, for each 1 SD increase in serum uric acid,
a 22% increased risk for ischemic stroke, and 13% in-
creased risk for all-cause mortality.
The association between serum uric acid and ischemic
stroke is in accordance with previous studies [5,19,20]. It
has been suggested that serum uric acid may have harm-
ful effects on platelet function [21] and cause endothelial
dysfunction [22]. Vannorsdall et al. [23] reported that even
a mild elevation of serum uric acid was associated with
cerebral ischemia among community-dwelling adults. It
was suggested that impaired vascular tone and endothelial
dysfunction could contribute to ischemic changes, because
they permit cerebrospinal fluid to cross the blood-brain
barrier and cause areas of edema [23].
Quite opposite to this, it has been claimed that treat-
ment with uric acid in combination with thrombolysis
would be of benefit to patients suffering from acute
stroke [24]. Uric acid is one of the most important en-
dogenous antioxidants in the human brain, and high circu-
lating uric acid could play a role against the deleterious
effect of free radicals produced upstream in the synthesis of
uric acid [24]. Accordingly, a J-curve relationship has been
observed between serum uric acid and occurrence of ische-
mic stroke [19]. Our study did, however, not reveal any
non-linear associations between serum uric acid and any of
the endpoints. In women, serum uric acid lost significance
as predictor for ischemic stroke when blood pressure andBMI were included as covariates. However, no gender inter-
action was observed. Differences in risk estimates for stroke
between genders, may relate to gender-specific differences
in vascular biology such as adaption to pro-inflammatory
stress. Vlachopoulos et al. [25] reported that in newly diag-
nosed hypertensive persons, uric acid was associated with
increased aortic stiffness in both genders, however a nega-
tive association with arterial wave reflection was observed
only in women. Such differences like this in vascular func-
tion could influence the tendency of developing stroke. The
Framingham study [11] also reported lack of independent
association of uric acid with stroke, but this is in contrast
to the gender specific analyses of the AMORIS-study [5].
However, BMI and use of antihypertensive medication was
not accounted for in the AMORIS study [5].
We observed a significant association of serum uric
acid with all-cause mortality, with a modest increase in
mortality risk in both genders. In the Framingham study
[11], no association was observed with all-cause mortal-
ity among the genders after adjustments for age, blood
pressure, smoking, BMI, total cholesterol, intake of alcohol
and medication. On the other hand, the NHANES study
[3] reported a 13% increased mortality risk in women in
fully adjusted analyses, but only non-significant associations
in men. The fact that serum uric acid levels in women tend
to increase during the fifth to the seventh decade due to
postmenopausal reduction in uric acid excretion [2,26],
whereas a flat (Figure 2) or slightly declining curve with
ageing is seen in men [11], may influence the association
with endpoints among the genders.
No independent association between increment in uric
acid and MI was observed in the present study. However,
Table 3 Associations of serum uric acid with adverse cardiovascular events and all-cause mortality
Hazard ratio (95% CI) per 1 SD increase in serum uric acid (87 μmol/L)
Men (n = 2696) P-value Women (n = 3004) P-value Men and women ( n = 5700) P-value
All-cause mortality
Unadjusted 1.01 (0.94, 1.09) 0.6 1.24 (1.14, 1.35) <0.001 1.10 (1.04, 1.17) <0.001
Age-adjusted 1.11 (1.03, 1.19) 0.005 1.12 (1.03, 1.22) 0.008 1.11 (1,05, 1.18) <0.001
Multivariable adjustment
Model 1 1.13 (1.04, 1.22) 0.003 1.22 (1.12, 1.33) <0.001 1.19 (1.14, 1.25) <0.001
Model 2 1.13 (1.05, 1.23) 0.003 1.20 (1.10, 1.31) 0.001 1.17 (1.01, 1.24) <0.001
Model 3 1.13 (1.04, 1.22) 0.005 1.20 (1.09, 1.32) <0.001 1.16 (1,09, 1.23) <0.001
Model 4 1.12 (1.04, 1.22) 0.005 1.20 (1.09, 1.31) <0.001 1.16 (1.09, 1.23) <0.001
Model 5 1.11 (1.02, 1.20) 0.02 1.16 (1.05, 1.29) 0.004 1.13 (1.06, 1.21) <0.001
Myocardial infarction
Unadjusted 1.15 (1.05, 1.26) 0.003 1.38 (1.20, 1.59) <0.001 1.21 (1.12, 1.31) <0.001
Age-adjusted 1.22 (1.11, 1.34) <0.001 1.21 (1.06, 1.40) 0.006 1.23 (1.14, 1.33) <0.001
Multivariable adjustment
Model 1 1.16 (1.05, 1.28) 0.004 1.16 (1.01, 1.35) 0.049 1.16 (1.08, 1.27) <0.001
Model 2 1.07 (0.95, 1.19) 0.25 1.09 (0.93, 1.27) 0.26 1.09 (0.99, 1.18) 0.09
Model 3 1.05 (0.94, 1.17) 0.3 1.10 (0.94, 1.29) 0.22 1.09 (0.10, 1.18) 0.06
Model 4 1.05 (0.95, 1.17) 0.3 1.09 (0.93, 1.27) 0.3 1.08 (0.99, 1.18) 0.09
Model 5 1.05 (0.94, 1.17) 0.4 1.06 (0.90, 1.25) 0.5 1.06 (0.97, 1.16) 0.19
Ischemic stroke
Unadjusted 1.13 (1.01, 1.28) 0.049 1.37 (1.17, 1.61) <0.001 1.21 (1.10, 1.33) <0.001
Age-adjusted 1.23 (1.08, 1.40) 0.001 1.20 (1.03, 1.40) 0.02 1.22 (1.11, 1.35) <0.001
Multivariable adjustment
Model 1 1.25 (1.10, 1.42) 0.001 1.13 (0.95, 1.33) 0.17 1.19 (1.07, 1.31) 0.001
Model 2 1.29 (1.13, 1.47) <0.001 1.13 (0.95, 1.34) 0.17 1.22 (1.09, 1.35) <0.001
Model 3 1.28 (1.11, 1.46) <0.001 1.13 (0.95, 1.35) 0.18 1.21 (1.09, 1.35) <0.001
Model 4 1.28 (1.12, 1.47) <0.001 1.12 (0.94, 1.34) 0.20 1.22 (1.09, 1.35) <0.001
Model 5 1.31 (1.14, 1.50) <0.001 1.13 (0.94, 1.36) 0.21 1.24 (1.11, 1.38) <0.001
The Tromsø Study.
Model 1: Age, body mass index (BMI), systolic blood pressure (SBP) and diastolic blood pressure (DBP).
Model 2: Model 1 + HDL-cholesterol and total cholesterol.
Model 3: Model 2 + use of diuretics and other antihypertensive medication.
Model 4: Model 3 + current smoking and physical activity (physical activity ≥1 hr per week; yes = 1 / no = 0), current smoking (yes = 1 / no = 0).
Model 5: Model 4 + renal factors added (GFR the CKD-EPI and log ACR: GFR: CKD-EPI formula [17]. Log ACR: log albumin/creatinine ratio, mean of 3 urine samples).
In analyses of men and women together, adjustment for gender is included in all models.
Number of events during follow up: 659 fatal- or non-fatal myocardial infarctions, 430 fatal- or non-fatal ischemic strokes, and 1433 deaths from all causes.
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expected, but on lipids. Total- and HDL-cholesterol abol-
ished the effect of uric acid on future MI. This is in con-
sistence with a recent study [27] on the predictive value
of uric acid on cardiovascular mortality among persons
with type 2 diabetes in the general population. The in-
clusion of HDL-cholesterol, LDL-cholesterol, triglycerides,
BMI, HbA1c and blood pressure as covariates abolished the
significance of a 40% risk increment found in subjects with
uric acid levels > 375 μmol/L in sex and age-adjusted ana-
lyses [27]. Subgroups with known diabetes or cardiovasculardisease were excluded in the present study, as we aimed to
examine the role of uric acid in a low-risk population. Suba-
nalyses where persons with diabetes or preexisting cardio-
vascular disease were included, did not change our results.
Neither did stratification according to uric acid values
above or less than the upper reference range. This is in con-
trast to the NHANES study [3], where an increased risk of
ischemic heart disease mortality was observed. Hazard ra-
tios for each 59 μmol/l increase in uric acid level were re-
ported to be 1.17 (95% CI 1.06-1.28) in men and 1.30 (95%
CI 1.17-1.45) in women [3]. However, in that study, BMI
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http://www.biomedcentral.com/1471-2261/13/115was higher than in the present study, and covariates such as
HDL-cholesterol and drug intake were not accounted for.
The Framingham Study [11] is one of the largest stud-
ies on the association of uric acid with CVD in the gen-
eral population. Our study differs from the Framingham
Study [11] in many ways. Mean age was 47 years in the
Framingham study compared with 60 years in the present
study, and thus mortality rate was lower in the Framingham
study (12.4 per 1000 person years compared to 18.9 per
1000 person years). In general, studies that have failed to
discern associations between uric acid and cardiovascular
disease have had shorter observation time, included youn-
ger persons, and had low number of events per-person-
years. As such they may have lacked the power to identify
the contribution of hyperuricemia to cardiovascular out-
comes [28]. The observation time in our study was longer
than in most previous studies, and this may explain why we
were able to detect associations in a study population where
high-risk subjects had been excluded (e.g., subjects with
diabetes and known CVD). It has been claimed that uric
acid is a more important risk factor among Afro Americans
than among Caucasians [3,11]. Our study shows that uric
acid is a risk factor in the Caucasian population as well.
Several mechanisms could cause the uric acid metabolic
pathway to be a CV risk factor. Uric acid may stimulate
vascular smooth cell proliferation, and reduce vascular ni-
tric oxide production. For a review, see [29]. The action of
xanthine oxidase leads to generation of superoxide anions
[30]. This could mean that xantine oxidase activity is the
key risk factor, with uric acid just an epiphenomenon. Uric
acid per se has been described as a scavenger with antioxi-
dant effects [29-32]. It is noteworthy that some prelimin-
ary intervention studies have shown that the xanthine
oxidase inhibitor Allopurinol lowered blood pressure in
hypertensive adolescents [33], and had anti-ischemic ef-
fects in patients with angina pectoris [34]. Allopurinol also
reduced cardiovascular and hospitalization risk in a small
study of patients with renal failure [35]. A recent study
found that hyperuricemia was significantly associated with
poor outcomes in heart failure patients without chronic
kidney disease, but not in hyperuricemic persons with
renal failure [36]. The latter could suggest that hyperurice-
mia may predict poor outcomes primarily as a marker of
xanthine oxidase activity, and not due to impaired renal
excretion of uric acid. Future intervention studies will
hopefully explore this important issue further.
A major shortcoming of our study is that serum uric
acid was done as a single measurement. Furthermore,
assessment was done in a population of Caucasians only,
so our results may not pertain to other ethnical groups.
The study is strengthened by the solid attendance rate,
a long follow-up time, the thorough validation of end-
points, and the ability to correct for confounding risk fac-
tors such as renal function, ACR, traditional cardiovascularrisk factors and the use of antihypertensive medication
and diuretics.
Conclusion
After multivariable adjustment, serum uric acid was sig-
nificantly associated with increased risk of future ische-
mic stroke in men and with all-cause mortality in both
genders. Associations of uric acid with myocardial in-
farction lost significance after adjustments for lipids. We
conclude that serum uric acid is an independent marker
of ischemic stroke in men, and all-cause mortality in both
genders in a Caucasian, general population. Gender-specific
analyses should be given priority in future studies.
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